SCHOTT Pharma (1SXP) Q3 2025 earnings summary

Executive summary

• Q3 revenue reached €256 million, up 3% year-over-year at constant currencies, driven by high-value solutions and efficiency improvements.

• EBITDA rose 11% year-over-year to €83 million, with a record margin of 31.7%, reflecting a favorable product mix and cost benefits.

• High-value solutions (HVS) revenue share increased by 5 percentage points to 60% in Q3, supporting strategic goals and innovation focus.

• Customer loyalty index reached 90 points, significantly above industry peers, reflecting strong customer relationships and product quality.

• For the first nine months, revenue grew 2.6% year-over-year to €738.6 million, with EBITDA up 11.2% to €212.9 million and margin at 28.8%.

Financial highlights

• Q3 revenue: €256 million (+3% year-over-year at constant currencies).

• Q3 EBITDA: €83 million (+11% year-over-year), margin 31.7%.

• Earnings per share for Q3: €0.30, with a marginal 1% decrease due to higher depreciation, lower financial results, and increased tax expenses.

• Capital expenditure in Q3: €38 million, up €14 million year-over-year.

• Free cash flow in Q3: €17 million, down from €34 million in Q3 2024, impacted by higher working capital and tax payments.

Outlook and guidance

• Organic revenue growth for FY2025 expected at around 6% at constant currencies, revised to the lower end of previous guidance.

• EBITDA margin for FY2025 guided to around 28%, above previous guidance and FY2024's 26.9%.

• CapEx for FY2025 reaffirmed at €140–160 million.

• Full-year tax rate anticipated at 22%, up from previously communicated 20%.

• Medium-term revenue growth target above 10% remains unchanged.